Skip to main content
Premium Trial:

Request an Annual Quote

Dante Labs, Abu Dhabi Stem Cells Center Ink Genetic Testing, mRNA Cancer Vaccine Development Deal

NEW YORK — Genomic analysis firm Dante Labs said on Wednesday that it has signed an agreement to provide genetic testing for Abu Dhabi Stem Cells Center (ADSCC), as well as work with the healthcare center to develop a platform to identify precision cancer treatments.

Under the terms of the deal, Dante will provide a range of clinical genetic testing to ADSCC patients at its Dubai-based lab. The partners have also launched an R&D program focused on developing personalized mRNA cancer vaccines.

Additional terms were not disclosed.

"This collaboration with ADSCC is an important step forward in our strategy to provide the best clinical genetic services now to United Arab Emirates and in the region," Dante CEO Andrea Riposati said in a statement. "The goal is that partnerships like this will pave the way to a much wider adoption of genomics in additional clinical fields."

Earlier this year, New York City-based Dante formed a drug discovery alliance with the Renato Dulbecco Foundation focused in the areas of cancer, COVID-19, and rare diseases. The company also recently agreed to refund certain customers for its COVID-19 and other PCR diagnostics following a business practice investigation by the UK's Competition and Markets Authority.